<!DOCTYPE html><html lang="en"><head><meta charset="utf-8"><meta http-equiv="X-UA-Compatible" content="IE=edge"><meta name="viewport" content="width=device-width,initial-scale=1"><title>Chemotherapy I - BHOLE</title><meta name="description" content="Chemotherapy IHallmarks of CancerChallengesMultiple mutationsHeterogeneityEpigeneticsTumor MicroenvironmentDrug Resistance:Chemotherapy:History:Types of ChemoTargetting the Cell CycleTherapeutic WindowDrug Resistance: Goldie-Coldman ModelCombination ChemotherapyRoute of Administration - 5-FUPharmacokineticsAlkylating AgentsAlkylating Mustards:General Mechanism:Reactivity:Notes on MustardsAlkylating Mustards: Cyclophosphamide and Ifosfamide are pro-drugsAlkylating Mustards: Cyclophosphamide and Ifosfamide and acrolein toxicityAlkylating Mustards: Ifosfamide Neurotoxicity:Alkylating NitrosoureasAlkylating TriazenesAlkylating Platinum&hellip;"><meta name="generator" content="Publii Open-Source CMS for Static Site"><link rel="canonical" href="https://BGASM.github.io/medNotes/chemotherapy-i.html"><link rel="alternate" type="application/atom+xml" href="https://BGASM.github.io/medNotes/feed.xml"><link rel="alternate" type="application/json" href="https://BGASM.github.io/medNotes/feed.json"><meta property="og:title" content="Chemotherapy I"><meta property="og:site_name" content="BHOLE"><meta property="og:description" content="Chemotherapy IHallmarks of CancerChallengesMultiple mutationsHeterogeneityEpigeneticsTumor MicroenvironmentDrug Resistance:Chemotherapy:History:Types of ChemoTargetting the Cell CycleTherapeutic WindowDrug Resistance: Goldie-Coldman ModelCombination ChemotherapyRoute of Administration - 5-FUPharmacokineticsAlkylating AgentsAlkylating Mustards:General Mechanism:Reactivity:Notes on MustardsAlkylating Mustards: Cyclophosphamide and Ifosfamide are pro-drugsAlkylating Mustards: Cyclophosphamide and Ifosfamide and acrolein toxicityAlkylating Mustards: Ifosfamide Neurotoxicity:Alkylating NitrosoureasAlkylating TriazenesAlkylating Platinum&hellip;"><meta property="og:url" content="https://BGASM.github.io/medNotes/chemotherapy-i.html"><meta property="og:type" content="article"><link rel="preconnect" href="https://fonts.gstatic.com/" crossorigin><link href="https://fonts.googleapis.com/css?family=Open+Sans:400,700|Roboto:400,700&amp;subset=latin-ext&amp;display=swap" rel="stylesheet"><style>:root{--body-font:'Open Sans',sans-serif;--heading-font:'Roboto',sans-serif;--logo-font:'Roboto',sans-serif;--menu-font:'Roboto',sans-serif}</style><link rel="stylesheet" href="https://BGASM.github.io/medNotes/assets/css/style.css?v=d2564d8d5f32cbb5488692bb93d80cc5"><script type="application/ld+json">{"@context":"http://schema.org","@type":"Article","mainEntityOfPage":{"@type":"WebPage","@id":"https://BGASM.github.io/medNotes/chemotherapy-i.html"},"headline":"Chemotherapy I","datePublished":"2020-12-03T21:18","dateModified":"2020-12-06T17:05","description":"Chemotherapy IHallmarks of CancerChallengesMultiple mutationsHeterogeneityEpigeneticsTumor MicroenvironmentDrug Resistance:Chemotherapy:History:Types of ChemoTargetting the Cell CycleTherapeutic WindowDrug Resistance: Goldie-Coldman ModelCombination ChemotherapyRoute of Administration - 5-FUPharmacokineticsAlkylating AgentsAlkylating Mustards:General Mechanism:Reactivity:Notes on MustardsAlkylating Mustards: Cyclophosphamide and Ifosfamide are pro-drugsAlkylating Mustards: Cyclophosphamide and Ifosfamide and acrolein toxicityAlkylating Mustards: Ifosfamide Neurotoxicity:Alkylating NitrosoureasAlkylating TriazenesAlkylating Platinum&hellip;","author":{"@type":"Person","name":"William Slattery"},"publisher":{"@type":"Organization","name":"William Slattery"}}</script></head><body><div class="site-container"><header class="top" id="js-header"><a class="logo" href="https://BGASM.github.io/medNotes/">BHOLE</a><nav class="navbar js-navbar"><button class="navbar__toggle js-toggle" aria-label="Menu" aria-haspopup="true" aria-expanded="false"><span class="navbar__toggle-box"><span class="navbar__toggle-inner">Menu</span></span></button><ul class="navbar__menu"><li><a href="https://github.com/BGASM" target="_self">My Github</a></li><li class="active-parent has-submenu"><span class="is-separator" aria-haspopup="true">Pharmacology</span><ul class="navbar__submenu level-2" aria-hidden="true"><li><a href="https://BGASM.github.io/medNotes/adrenergic-and-cholinergic-systems.html" target="_self">Adrenergic and Cholinergic I</a></li><li><a href="https://BGASM.github.io/medNotes/adrenergic-and-cholinergic-systems-ii.html" target="_self">Adrenergic and Cholinergic II</a></li><li><a href="https://BGASM.github.io/medNotes/adrenergic-and-cholinergic-pharm-iii.html" target="_self">Adrenergic and Cholinergic III</a></li><li><a href="https://BGASM.github.io/medNotes/adrenergic-inhibitors.html" target="_self">Adrenergic and Cholinergic IV</a></li><li><a href="https://BGASM.github.io/medNotes/adrenergic_cholinergic-v.html" target="_self">Adrenergic and Cholinergic V</a></li><li class="active"><a href="https://BGASM.github.io/medNotes/chemotherapy-i.html" target="_self">Chemotherapy I</a></li><li><a href="https://BGASM.github.io/medNotes/chemotherapy-ii.html" target="_self">Chemotherapy II</a></li></ul></li><li class="has-submenu"><span class="is-separator" aria-haspopup="true">Pathophysiology</span><ul class="navbar__submenu level-2" aria-hidden="true"><li><a href="https://BGASM.github.io/medNotes/edema-congestion-and-hemostasis.html" target="_self">Edema Congestion and Hemostasis</a></li><li><a href="https://BGASM.github.io/medNotes/hemorrhage-thrombosis-and-embolism-2.html" target="_self">Hemorrhage Thrombosis and Embolism</a></li><li><a href="https://BGASM.github.io/medNotes/infarction-shock-and-dic.html" target="_self">Infarction Shock and DIC</a></li></ul></li><li class="has-submenu"><span class="is-separator" aria-haspopup="true">MMG</span><ul class="navbar__submenu level-2" aria-hidden="true"><li><a href="https://BGASM.github.io/medNotes/virology-i.html" target="_self">Virology I</a></li><li><a href="https://BGASM.github.io/medNotes/virology-ii.html" target="_self">Virology II</a></li><li><a href="https://BGASM.github.io/medNotes/virology-iii.html" target="_self">Virology III</a></li><li><a href="https://BGASM.github.io/medNotes/virology-v.html" target="_self">Virology V</a></li><li><a href="https://BGASM.github.io/medNotes/virology-vii.html" target="_self">Virology VII</a></li></ul></li></ul></nav></header><main><article class="post"><div class="hero"><figure class="hero__image hero__image--overlay"><img src="https://BGASM.github.io/medNotes/media/website/Jul24_GettyImages-582759294_neurons-scaled.jpg" srcset="https://BGASM.github.io/medNotes/media/website/responsive/Jul24_GettyImages-582759294_neurons-scaled-xs.jpg 300w, https://BGASM.github.io/medNotes/media/website/responsive/Jul24_GettyImages-582759294_neurons-scaled-sm.jpg 480w, https://BGASM.github.io/medNotes/media/website/responsive/Jul24_GettyImages-582759294_neurons-scaled-md.jpg 768w, https://BGASM.github.io/medNotes/media/website/responsive/Jul24_GettyImages-582759294_neurons-scaled-lg.jpg 1024w, https://BGASM.github.io/medNotes/media/website/responsive/Jul24_GettyImages-582759294_neurons-scaled-xl.jpg 1360w, https://BGASM.github.io/medNotes/media/website/responsive/Jul24_GettyImages-582759294_neurons-scaled-2xl.jpg 1600w" sizes="(max-width: 1600px) 100vw, 1600px" loading="eager" alt=""></figure><header class="hero__content"><div class="wrapper"><div class="post__meta"><time datetime="2020-12-03T21:18">December 3, 2020</time></div><h1>Chemotherapy I</h1><div class="post__meta post__meta--author"><a href="https://BGASM.github.io/medNotes/authors/william-slattery/" class="feed__author invert">William Slattery</a></div></div></header></div><div class="wrapper post__entry"><ul><li><a href="#chemotherapy-i">Chemotherapy I</a><ul><li><a href="#hallmarks-of-cancer">Hallmarks of Cancer</a><ul><li><a href="#challenges">Challenges</a></li></ul></li><li><a href="#multiple-mutations">Multiple mutations</a></li><li><a href="#heterogeneity">Heterogeneity</a></li><li><a href="#epigenetics">Epigenetics</a></li><li><a href="#tumor-microenvironment">Tumor Microenvironment</a></li><li><a href="#drug-resistance">Drug Resistance:</a><ul><li><a href="#chemotherapy">Chemotherapy:</a></li></ul></li><li><a href="#history">History:</a></li></ul></li><li><a href="#types-of-chemo">Types of Chemo</a><ul><li><a href="#targetting-the-cell-cycle">Targetting the Cell Cycle</a></li><li><a href="#therapeutic-window">Therapeutic Window</a></li><li><a href="#drug-resistance-goldie-coldman-model">Drug Resistance: Goldie-Coldman Model</a></li><li><a href="#combination-chemotherapy">Combination Chemotherapy</a></li><li><a href="#route-of-administration---5-fu">Route of Administration - 5-FU</a></li><li><a href="#pharmacokinetics">Pharmacokinetics</a></li></ul></li><li><a href="#alkylating-agents">Alkylating Agents</a><ul><li><a href="#alkylating-mustards">Alkylating Mustards:</a><ul><li><a href="#general-mechanism">General Mechanism:</a></li><li><a href="#reactivity">Reactivity:</a></li><li><a href="#notes-on-mustards">Notes on Mustards</a><ul><li><a href="#alkylating-mustards-cyclophosphamide-and-ifosfamide-are-pro-drugs">Alkylating Mustards: <strong>Cyclophosphamide and Ifosfamide</strong> are <strong>pro-drugs</strong></a></li><li><a href="#alkylating-mustards-cyclophosphamide-and-ifosfamide-and-acrolein-toxicity">Alkylating Mustards: <strong>Cyclophosphamide and Ifosfamide</strong> and acrolein toxicity</a></li><li><a href="#alkylating-mustards-ifosfamide-neurotoxicity">Alkylating Mustards: Ifosfamide Neurotoxicity:</a></li></ul></li><li><a href="#alkylating-nitrosoureas">Alkylating Nitrosoureas</a></li><li><a href="#alkylating-triazenes">Alkylating Triazenes</a></li><li><a href="#alkylating-platinum-complexes">Alkylating Platinum Complexes</a></li><li><a href="#alkylating-miscellaneous-procarbazine">Alkylating Miscellaneous: Procarbazine</a></li></ul></li><li><a href="#summary-of-alkylating">Summary of Alkylating:</a></li><li><a href="#summary-of-alkylating-agent-toxicity">Summary of Alkylating Agent Toxicity:</a><h2 id="chemotherapy-i">Chemotherapy I</h2></li></ul></li><li>Oncogene vs Tumor Suppressor | Gain of Function vs Loss of Function</li><li>Treating oncogenes the goal is to suppress<ul><li>e.g. Tyrosine kinase inhibitor</li></ul></li><li>Treating suppressor genes goal is to activate<ul><li>e.g. MAB cetuximab, which activates p53.<h4 id="hallmarks-of-cancer">Hallmarks of Cancer</h4></li></ul></li><li>Sustained proliferation</li><li>Evade growth suppressors</li><li>Enable replicative immortality</li><li>Resist celld eath</li><li>Activate invastion and metastasis</li><li>Induce angiogenesis</li><li>Genome instability and mutation</li><li>Avoid immune destruction</li><li>Deregulate cellular metabolism</li><li>Tumor promoting inflammation</li><li><figure class="post__image"><img loading="lazy" src="https://BGASM.github.io/medNotes/media/posts/9/target.JPG" sizes="(max-width: 48em) 100vw, 768px" srcset="https://BGASM.github.io/medNotes/media/posts/9/responsive/target-xs.JPG 300w, https://BGASM.github.io/medNotes/media/posts/9/responsive/target-sm.JPG 480w, https://BGASM.github.io/medNotes/media/posts/9/responsive/target-md.JPG 768w, https://BGASM.github.io/medNotes/media/posts/9/responsive/target-lg.JPG 1024w, https://BGASM.github.io/medNotes/media/posts/9/responsive/target-xl.JPG 1360w, https://BGASM.github.io/medNotes/media/posts/9/responsive/target-2xl.JPG 1600w" alt="Targetting Cancer" width="716" height="528"></figure><h3 id="challenges">Challenges</h3><h4 id="multiple-mutations">Multiple mutations</h4><h4 id="heterogeneity">Heterogeneity</h4><ul><li>2/3 of mutation from single biopsy not detected in different regions of the same tumor<h4 id="epigenetics">Epigenetics</h4></li><li>Normal cells acquire gentic and epigenetic alterations</li><li>Trying to treat cancer can exert additional pressure that accerlates its development of resistant</li><li>Epigenetic therapy can reverse these and restore sensitivity to treatment</li><li>Epigenetic targets enzymes - less toxic than chemo.</li><li><strong>Great if use in combination therapy</strong><h4 id="tumor-microenvironment">Tumor Microenvironment</h4></li></ul></li><li>Multiple cell types that support tumor growth<ul><li><strong>Immune cells</strong></li><li><strong>Fibroblasts</strong></li><li><strong>Endothelial cells</strong></li><li><strong>Vasculature</strong></li><li><em>Pancreatic cancer is not majorally cancerous cells, large portion is *</em>fibroblast***</li></ul></li><li>These microenvironment cells are all <strong>targetable</strong><h4 id="drug-resistance">Drug Resistance:</h4><ul><li><strong>P-glycoprotein efflux pumps</strong> extrude chemotherapy drugs</li><li>Drug metabolism</li><li>Drug sequestration</li><li>Alter signal transduction pathways</li><li>Evade or ignore programmed cell death<h3 id="chemotherapy">Chemotherapy:</h3></li><li>Dev 1940-1960 for solid tumors, hematological malignancies</li><li>Integrated with surgery and radiation</li><li>Obstacles:<ul><li>R</li><li>Hurt normal cells<h4 id="history">History:</h4></li><li>Mechlorethamine</li><li>Anti-metabolites<ul><li>Methotrexate and 5-fu</li></ul></li><li>Vinca Alkaloid</li><li>Cisplatin to inhibit cell division and cure solid tumors</li><li>Cure of Hodgkin’s disease and ALL</li><li>Adjuvant chemotherapy</li><li>Cure of testicular cancer (vinblastine + bleomycin + cisplatin)</li><li>Targeted Therapy:<ul><li>Gleevec - RTK for CML</li><li>Rituximab - NHL<h2 id="types-of-chemo">Types of Chemo</h2></li></ul></li></ul></li></ul></li><li><strong>Primary Induction</strong><ul><li><strong>advanced and no alternative</strong></li><li>Palliative</li><li><strong>Improve quality of life</strong></li><li>Prolong time to tumor progression (TTP)</li></ul></li><li><strong>Neoaduvnat</strong><pre><code>- localized cancer
- Not completely effective
- Used when surgery is not possible</code></pre></li><li><strong>Adjuvant</strong><pre><code>- follow surgery and radiation
- Reduce incidence of local and systemic recurrence
- **Improve overall survival** **OS**
- **Prolong disease free survival** **DFS**</code></pre><h3 id="targetting-the-cell-cycle">Targetting the Cell Cycle</h3></li><li><figure class="post__image"><img loading="lazy" src="https://BGASM.github.io/medNotes/media/posts/9/CELLCYCLE.png" sizes="(max-width: 48em) 100vw, 768px" srcset="https://BGASM.github.io/medNotes/media/posts/9/responsive/CELLCYCLE-xs.png 300w, https://BGASM.github.io/medNotes/media/posts/9/responsive/CELLCYCLE-sm.png 480w, https://BGASM.github.io/medNotes/media/posts/9/responsive/CELLCYCLE-md.png 768w, https://BGASM.github.io/medNotes/media/posts/9/responsive/CELLCYCLE-lg.png 1024w, https://BGASM.github.io/medNotes/media/posts/9/responsive/CELLCYCLE-xl.png 1360w, https://BGASM.github.io/medNotes/media/posts/9/responsive/CELLCYCLE-2xl.png 1600w" alt="Cell Cycle" width="1498" height="779"></figure></li><li>Cell survival exponentially related to dose</li><li>Slope of curve related to rate of cell proliferation</li><li><strong>Effective</strong> against those cells that <strong>proliferate rapidly</strong></li><li>Cause of Side Effects<ul><li><strong>Bone marrow</strong> stem cells: Immunocompromise</li><li>GI mucosal cells:</li><li>Hair Follicles: Alopecia</li><li>Ovaries testes<h3 id="therapeutic-window">Therapeutic Window</h3></li><li>Goals are to maximize efficacy and limit tocicity</li><li>Usually use maximum tolerated dose<h3 id="drug-resistance-goldie-coldman-model">Drug Resistance: Goldie-Coldman Model</h3><ul><li>Drug resistance probability is dependednt on intrinsic genetic instabillity</li><li>Even the <em>smallest detectable tumor contains at least 1 drug-resistant clone</em>.</li></ul></li><li><strong>Use all effective chemo drugs</strong><h3 id="combination-chemotherapy">Combination Chemotherapy</h3></li></ul></li><li><figure class="post__image"><img loading="lazy" src="https://BGASM.github.io/medNotes/media/posts/9/combo.JPG" sizes="(max-width: 48em) 100vw, 768px" srcset="https://BGASM.github.io/medNotes/media/posts/9/responsive/combo-xs.JPG 300w, https://BGASM.github.io/medNotes/media/posts/9/responsive/combo-sm.JPG 480w, https://BGASM.github.io/medNotes/media/posts/9/responsive/combo-md.JPG 768w, https://BGASM.github.io/medNotes/media/posts/9/responsive/combo-lg.JPG 1024w, https://BGASM.github.io/medNotes/media/posts/9/responsive/combo-xl.JPG 1360w, https://BGASM.github.io/medNotes/media/posts/9/responsive/combo-2xl.JPG 1600w" alt="Combo" width="1578" height="906"></figure><h3 id="route-of-administration---5-fu">Route of Administration - 5-FU</h3></li><li>IV bolus dose vs IV continuous infusion<ul><li>IV Bolous: Incorporate into cellular RNA and myelosuppression</li><li>IV Continuous: Incorporate into cellular DNA but skin toxicity</li></ul></li><li>Intermittent dose<ul><li>600mg/m2/cycle</li><li>No cardiac or bladder toxicity</li><li>Secondary malignancies can develop</li></ul></li><li>Single high dose<ul><li>Cardiac toxicity</li><li>Hemorrhagic cystitis</li></ul></li><li>Daily Dose<ul><li>Hemorrhagic cystitis</li><li>Secondary Malignancies<h3 id="pharmacokinetics">Pharmacokinetics</h3></li></ul></li><li>Phramocokinetics represents the kinetics of accumulation and disapperance from plasma</li></ul><h2 id="alkylating-agents">Alkylating Agents</h2><ul><li>Classes:<ol><li><strong>Nitrogen mustards</strong></li><li><strong>Nitrosoureas</strong></li><li><strong>Triazenes</strong></li><li><strong>Platinum complexes</strong><h3 id="alkylating-mustards">Alkylating Mustards:</h3><h4 id="general-mechanism">General Mechanism:</h4></li></ol><ul><li>Drug activated into <em>reative intermediates</em> that <strong>form adducts</strong> at N7 position of guanine in DNA</li><li>Loss of the guanine base (<em>depurination</em>) or miscoding of abnormal base pairing</li><li>Strand break or cross-linking of DNA</li><li>Cell death</li><li><figure class="post__image"><img loading="lazy" src="https://BGASM.github.io/medNotes/media/posts/9/alkylate.JPG" sizes="(max-width: 48em) 100vw, 768px" srcset="https://BGASM.github.io/medNotes/media/posts/9/responsive/alkylate-xs.JPG 300w, https://BGASM.github.io/medNotes/media/posts/9/responsive/alkylate-sm.JPG 480w, https://BGASM.github.io/medNotes/media/posts/9/responsive/alkylate-md.JPG 768w, https://BGASM.github.io/medNotes/media/posts/9/responsive/alkylate-lg.JPG 1024w, https://BGASM.github.io/medNotes/media/posts/9/responsive/alkylate-xl.JPG 1360w, https://BGASM.github.io/medNotes/media/posts/9/responsive/alkylate-2xl.JPG 1600w" alt="Alkylate" width="876" height="659"></figure><pre><code>Alkylating groups on nitrogen mustard act as &quot;warhead&quot;
N7 on guanine acts as electron donor, forming adduct
React with 2nd guanine, leading to depurination</code></pre><h4 id="reactivity">Reactivity:</h4></li></ul></li><li>Reactivity can be reduced by adding aromatic ring to warhead.</li><li>Less reactivity allows for drug to be given orally.<ul><li>Elderly patients with multiple myeloma or CLL<h4 id="notes-on-mustards">Notes on Mustards</h4><h5 id="alkylating-mustards-cyclophosphamide-and-ifosfamide-are-pro-drugs">Alkylating Mustards: <strong>Cyclophosphamide and Ifosfamide</strong> are <strong>pro-drugs</strong></h5></li><li>Share same active cytotoxic ingredient: phophoramide mustard</li><li>Both metabolized to <strong>acrolein</strong> (toxic to bladder - <strong>hemorrhagic cystitis</strong>)<h5 id="alkylating-mustards-cyclophosphamide-and-ifosfamide-and-acrolein-toxicity">Alkylating Mustards: <strong>Cyclophosphamide and Ifosfamide</strong> and acrolein toxicity</h5></li><li>Hemorrhagic cystitis is dose and schedule dependent</li><li>Acreolin react with nucleophiles in uroepithelium:<ul><li>Prevent with adequate hydration or MESNA</li><li>MESNA inactivates acrolein by binding to and preventing reaction with cellular nucleophiles</li><li>MESNA can prevent hemorrhagic cystitis, but not treat it.</li><li>Treatment is hydration with saline</li><li><strong>Blood in urine of PT treated with cyclophosphamide</strong> is an early warning sign of bladder tox.<h5 id="alkylating-mustards-ifosfamide-neurotoxicity">Alkylating Mustards: Ifosfamide Neurotoxicity:</h5></li></ul></li><li>Ifosfamide shares hemorrhagic cystits toxicity with cyclophosphamide - <strong>acrolein</strong></li><li>Also has Unique CNS neurotoxicity:<ul><li>Chloroacetaldehyde distrub mitochondrial respiratory chain</li><li><strong>Methylene blue is the antidote</strong>. Inhibits formation of <strong>chloroacetaldehyde</strong></li><li><figure class="post__image"><img loading="lazy" src="https://BGASM.github.io/medNotes/media/posts/9/ifosamide.JPG" sizes="(max-width: 48em) 100vw, 768px" srcset="https://BGASM.github.io/medNotes/media/posts/9/responsive/ifosamide-xs.JPG 300w, https://BGASM.github.io/medNotes/media/posts/9/responsive/ifosamide-sm.JPG 480w, https://BGASM.github.io/medNotes/media/posts/9/responsive/ifosamide-md.JPG 768w, https://BGASM.github.io/medNotes/media/posts/9/responsive/ifosamide-lg.JPG 1024w, https://BGASM.github.io/medNotes/media/posts/9/responsive/ifosamide-xl.JPG 1360w, https://BGASM.github.io/medNotes/media/posts/9/responsive/ifosamide-2xl.JPG 1600w" alt="Ifosamide" width="871" height="657"></figure><h4 id="alkylating-nitrosoureas">Alkylating Nitrosoureas</h4></li></ul></li></ul></li><li>Liberate organic isocyanates</li><li>React with lysine residues</li><li>Inactivation of protein, esp DNA repair enzyme</li><li><strong>Highly lipophillic</strong> and used to treat brain tumor because <strong>cross BBB</strong><h4 id="alkylating-triazenes">Alkylating Triazenes</h4></li><li><strong>Methylate</strong> DNA at O6 and N7 positions on <strong>Guanine</strong></li><li>Temozolamide is <strong>highly lipophillic</strong></li></ul><h4 id="alkylating-platinum-complexes">Alkylating Platinum Complexes</h4><ul><li>React with DNA to produce inter and intra strand crosslinnks between adjacent guanines, or guanine and adeninge</li><li>Produce <strong>DNA adducts</strong> that inhibit replication and transcription</li><li><strong>Cisplatin, Carboplatin</strong>:<ul><li>Good for <strong>neck cancer</strong>.</li><li>Cistplatin has <strong>High nephrotoxicity</strong></li><li>Carboplatin has <strong>low nephrotoxicity</strong></li></ul></li><li>Oxaliplatin:<ul><li>More effective for <strong>colon and pancreatic</strong></li></ul><strong>- Nephrotoxicity</strong></li><li>Oxaliplatin more potent than cisplatin in vitro and requires fewer DNA adducts to achieve cytotoxicity</li><li>Carboplatin is a larger molecule than cisplatin; longer retention and different toxicities (less)</li><li><strong>Cytotoxic activity against different tumors and toxicity NOT the same with different platinum compounds</strong><h4 id="alkylating-miscellaneous-procarbazine">Alkylating Miscellaneous: Procarbazine</h4></li><li>MAOI: MAO - Inhibitor<h3 id="summary-of-alkylating">Summary of Alkylating:</h3></li><li>Share similar mechanism of action:<ul><li>Activated to reactive</li><li>Form adducts with cellular macromolecules</li><li>Methylkate DNA gernate isocyanates</li><li>Same adverse effects:</li><li>Hemorrhagic cystitis</li><li>CNS toxicity</li><li>Nephrotoxicity and neuropathy</li></ul></li><li>Lipophillic agents have unique applications<h3 id="summary-of-alkylating-agent-toxicity">Summary of Alkylating Agent Toxicity:</h3><ul><li>More toxic to normal, rapidly proliferating cells</li><li>Non-cell cycle specific</li><li>Damage DNA</li><li>Increase mutations</li><li>Secondary malignancies are long-term<ul><li>Leukemias</li><li>Myelodysplastic syndrome</li></ul></li></ul></li></ul></div><footer class="wrapper post__footer"><p class="post__last-updated">This article was updated on December 6, 2020</p></footer></article><nav class="post__nav"><div class="post__nav-inner"><div class="post__nav-prev"><svg width="1.041em" height="0.416em" aria-hidden="true"><use xlink:href="https://BGASM.github.io/medNotes/assets/svg/svg-map.svg#arrow-prev"/></svg> <a href="https://BGASM.github.io/medNotes/infarction-shock-and-dic.html" class="invert post__nav-link" rel="prev"><span>Previous</span> PSL III Infarction Shock and DIC</a></div><div class="post__nav-next"><a href="https://BGASM.github.io/medNotes/chemotherapy-ii.html" class="invert post__nav-link" rel="next"><span>Next</span> Chemotherapy II </a><svg width="1.041em" height="0.416em" aria-hidden="true"><use xlink:href="https://BGASM.github.io/medNotes/assets/svg/svg-map.svg#arrow-next"/></svg></div></div></nav></main><footer class="footer"><div class="footer__copyright"><p>Powered by <a href="https://getpublii.com" target="_blank" rel="nofollow noopener">Publii</a></p></div><button class="footer__bttop js-footer__bttop" aria-label="Back to top"><svg><title>Back to top</title><use xlink:href="https://BGASM.github.io/medNotes/assets/svg/svg-map.svg#toparrow"/></svg></button></footer></div><script>window.publiiThemeMenuConfig = {    
        mobileMenuMode: 'overlay',
        animationSpeed: 300,
        submenuWidth: 'auto',
        doubleClickTime: 500,
        mobileMenuExpandableSubmenus: true, 
        relatedContainerForOverlayMenuSelector: '.top',
   };</script><script defer="defer" src="https://BGASM.github.io/medNotes/assets/js/scripts.min.js?v=f4c4d35432d0e17d212f2fae4e0f8247"></script><script>var images = document.querySelectorAll('img[loading]');

        for (var i = 0; i < images.length; i++) {
            if (images[i].complete) {
                images[i].classList.add('is-loaded');
            } else {
                images[i].addEventListener('load', function () {
                    this.classList.add('is-loaded');
                }, false);
            }
        }</script></body></html>